Renal carcinoma
MONDO:0005206A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis. The majority are renal cell carcinomas. Kidney carcinomas usually affect middle aged and elderly adults. Hematuria, abdominal pain, and a palpable mass are common symptoms.
Also known as: kidney (including renal cell) cancer, kidney (renal) cancer, kidney cancer, renal cancer, carcinoma of kidney, kidney carcinoma, renal carcinoma
3460 clinical trials for this condition and its sub-types, 85 tagged with Renal carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Renal carcinoma
-
Renal cell carcinoma 611 trials · 710 incl. sub-types
11 sub-types
- Renal cell adenocarcinoma 98 trials · 251 incl. sub-types Sub-types →
- Nonpapillary renal cell carcinoma 156 trials · 246 incl. sub-types Sub-types →
- Adrenal cortex carcinoma 42 trials Sub-types →
- Collecting duct carcinoma 18 trials
- Kidney medullary carcinoma 10 trials · 13 incl. sub-types Sub-types →
- MIT family translocation renal cell carcinoma 6 trials Sub-types →
- Wolffian duct adenocarcinoma 2 trials
- Acquired cystic disease-associated renal cell carcinoma 0 trials
- Cystic renal cell carcinoma 0 trials
- Mucinous tubular and spindle renal cell carcinoma 0 trials
- Renal pelvis adenocarcinoma 0 trials
-
Renal pelvis carcinoma 15 trials · 22 incl. sub-types
4 sub-types
- Renal pelvis urothelial carcinoma 16 trials Sub-types →
- Carcinoma in situ of renal pelvis 0 trials
- Renal pelvis adenocarcinoma 0 trials
- Renal pelvis squamous cell carcinoma 0 trials
-
Kidney carcinoma in situ 0 trials
1 sub-type
- Carcinoma in situ of renal pelvis 0 trials
Most studied deeper sub-types
-
New cancer drug AUR109 tested in three tumor types – trial halted early
Disease control Stopped earlyThis phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…
Phase 2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill shows promise for Hard-to-Treat kidney cancer
Disease control Stopped earlyThis study tested an oral drug called NKT2152 in people with advanced clear cell renal cell carcinoma that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The trial was terminated early, but the data may still help guid…
Phase 1/2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Kidney cancer combo trial halted early – what we know
Disease control Stopped earlyThis study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was …
Phase 2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Virtual reality could help measure and treat cancer pain, study suggests
Knowledge-focused Stopped earlyThis study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…
Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Radiation therapy study seeks immune clues in blood
Knowledge-focused Stopped earlyThis study followed 28 adults with liver, colorectal, melanoma, or kidney cancers who received high-dose radiation therapy. Researchers collected blood samples before, during, and after treatment to track immune cells and other markers. The goal was to learn how the immune system…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC